Pharm
Integrase Strand Transfer Inhibitor
search
Integrase Strand Transfer Inhibitor
, Integrase Inhibitor, InSTI
See Also
Anti-Retroviral Therapy
Cabotegravir
Indications
HIV Infection
Anti-retroviral
naive or experienced patients as part of combination therapy
Mechanism
Anti-retroviral
agent
Integrase Strand Transfer Inhibitor
Prevents viral DNA from integrating into host DNA
Blocks the integrase enzyme
Medications
Single Agents
Bictegravir
Only available as combination agent
Biktarvy
contains
Bictegravir
(an InSTI) and 2
nRTI
agents,
Emtricitabine
(FTC),
Tenofovir
(TAF)
Cabotegravir
(
Vocabria
)
See
Cabotegravir
Cabenuva
(
Cabotegravir
and
Rilpivirine
) IM Monthly Injection is used for
HIV Infection
Treatment
Cabotegravir
(
Apretude
) IM Monthly Injection is indicated in
HIV Pre-exposure Prophylaxis
or PReP
Dolutegravir
(Tivacay)
See
Dolutegravir
Dolutegravir
and
Lamivudine
(
Dovato
)
Dolutegravir
50 mg AND
Rilpivirine
25 mg (
Juluca
)
Raltegravir
(
Isentress
)
Safety
Lactation
Unknown safety in
Lactation
Pregnancy
Dolutegravir
(Tivacay)
Unsafe in pregnancy
Associated with
Neural Tube Defect
s
May be a class effect (unclear if this applies to other Integrase Inhibitors)
Efficacy
Drug resistance is common
Adverse Effects
Gene
ral
Weight gain
Hyperglycemia
Hyperlipidemia
Weight gain (2 to 7 kg, more in women)
Adverse Effects
Raltegravir
Diarrhea
Nausea
Headache
Serum Creatinine
phosphokinase (CPK) increases
Mild
Serum Creatinine
increase without affecting
Renal Function
(
Dolutegravir
)
Myopathy
Rhabdomyolysis
Insomnia
Liver Function Test
abnormalities (
Cabotegravir
)
Drug Interactions
Typically fewer
Drug Interaction
s than other
Anti-Retroviral Agents
Phenytoin
Rifampin
St John's Wort
Avoid taking at the same time as
Calcium
,
Magnesium
, aluminum and iron containing agents
References
(2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]
Type your search phrase here